PhRMA, EC unhappy with Indian patent examination draft
This article was originally published in Scrip
Big pharma believes that India's draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals uses language that generally "disparages" drug patents and that the implied scope of these guidelines exceeds that of the controversial Section 3d of India's Patent Act.
You may also be interested in...
Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’
India has prohibited exports of hydroxychloroquine, though with concessions in specific instances, days after a national task force recommended the drug for the prophylaxis of SARS-CoV-2 infections. Home market supplies of the drug also appear strained for now.
Alembic says it is 'comfortably placed' in terms of inventories and is seeing improving API supplies from China. The only area of some concern is outbound logistics against a backdrop of flights being halted and population lock-downs.